# Project Status & Execution Dashboard

**Project Title:** A Robust Multimodal AI Framework for Multi-Cancer Classification Under Missing Modalities  
**Cohort:** TCGA Pan-Cancer (BRCA, HNSC, LGG, THCA; 2,263 total patient samples across 4 modalities)  
**Last Updated:** 2026-10-21 (Audited & Reconciled)  
**Overall Project Health:** 🟢 **100% Complete, Verified, & Statistically Reconciled**

---

## 1. Overall Stage Status & Gate Verification

| Stage | Name | Status | Key Output / Deliverable | Gate Criteria |
|:---:|:---|:---:|:---|:---:|
| **Stage A** | Dataset Audit & Verification | ✅ **Complete** | `reports/dataset_audit.json`, 26/26 checks passed | Passed |
| **Stage B** | Research Protocol & Docs | ✅ **Complete** | Complete 12-document suite in `docs/` & `configs/` | Passed |
| **Stage C** | Data Pipeline & Splitting | ✅ **Complete** | `data/processed/`, `data/splits/splits.csv` (70/15/15); 0 patient/sample leakage | Passed |
| **Stage D** | Baseline Models (D1–D6) | ✅ **Complete** | All 6 baselines evaluated across 5 seeds in `artifacts/metrics/` (D5/D6 complete-only) | Passed |
| **Stage E** | Multimodal Fusion Model | ✅ **Complete** | Proposed Cross-Attention Architecture (S1: 0.9956, S2: 0.9950) | Passed |
| **Stage F** | Missing-Modality Robustness | ✅ **Complete** | All 15 conditions (C0–C14) evaluated; S2 gives +8.52% F1 empirical gain on C12 | Passed |
| **Stage G** | Explainability & Biomarkers | ✅ **Complete** | Descriptive attention routing & literature-concordant feature attributions | Passed |
| **Stage H** | Publication Visualizations | ✅ **Complete** | `artifacts/figures/` (Figs 1–4), 300 DPI publication charts | Passed |
| **Stage I** | Automated Test Suite | ✅ **Complete** | `tests/test_pipeline.py` (8/8 pytest unit tests passed, including masking invariance) | Passed |
| **Stage J** | Systematic Ablation Suite | ✅ **Complete** | `artifacts/metrics/ablation_study.json` (Tokens, Dropout, Dim, Heads) | Passed |
| **Stage K** | Statistical Significance Tests | ✅ **Complete** | `reports/statistical_significance_report.md` (Paired t, Cohen's d, Wilcoxon, 95% CI) | Passed |
| **Stage L** | Research Paper Manuscript | ✅ **Complete** | `reports/research_paper_draft.md` (Working pre-peer-review research draft) | Passed |

---

## 2. Detailed Stage Results & Empirical Findings

### Stage A: Dataset Audit & Quality Control
- **Total cohort:** Exactly 2,263 patient samples across 4 target cancer classes:
  - BRCA (Label 2): 757 samples
  - HNSC (Label 8): 506 samples
  - LGG (Label 13): 506 samples
  - THCA (Label 27): 494 samples
- **Patient Uniqueness:** Verified via `scripts/verify_patient_leakage.py` that 2,263 unique sample IDs correspond to 2,263 unique patient IDs (zero multi-sample patients).
- **Modality features:** mRNA (3,217), miRNA (383), CNV (3,105), DNA Methylation (3,139). Total: 9,844 features.
- **Verification:** 26/26 automated audit checks passed. Zero missing values in raw inputs. Barcodes aligned across all 4 matrices.

### Stage B: Research Documentation & Protocol Architecture
- Complete 12-document research suite created in `docs/`:
  - `research_questions.md`, `experimental_protocol.md`, `model_architecture.md`, `missing_modality_protocol.md`, `evaluation_protocol.md`, `explainability_protocol.md`, `reproducibility.md`, `limitations_and_risks.md`, `decision_log.md` (DEC-001 through DEC-007), `experiment_log.md`, `data_dictionary.md`, `dataset_audit.md`.
- Strict configuration files in `configs/`: `data.yaml`, `model.yaml`, `experiment.yaml`.

### Stage C: Preprocessing & Anti-Leakage Partitioning
- **Splits:** Stratified 70% Train (1,584), 15% Val (339), 15% Test (340).
- **Executed Preprocessing Operations:**
  - `mRNA`, `miRNA`, `CNV`: Fitted strictly on training set using `StandardScaler` (z-score normalization) and zero-variance filtering (`variance_threshold = 0.0`). All features retained.
  - `Methy`: Fitted strictly on training set using `MinMaxScaler` ($[0, 1]$ bounded scaling) and zero-variance filtering. All 3,139 features retained.
- **Leak-Free Disjointness:** Verified pairwise zero overlap at both sample and patient level:
  $$\text{Train} \cap \text{Val} = \emptyset, \quad \text{Train} \cap \text{Test} = \emptyset, \quad \text{Val} \cap \text{Test} = \emptyset$$

### Stage D: Baseline Models (Multi-Seed Results Across 5 Seeds: 42, 123, 456, 789, 1024)

| Exp ID | Model Architecture | Modality / Features | Test Macro-F1 (Mean ± Std) | 95% Confidence Interval | Seed Variance? | Status |
|:---:|:---|:---:|:---:|:---:|:---:|:---:|
| **D1** | Single-Modality MLP | mRNA (3,217) | **0.9961 ± 0.0015** | [0.9943, 0.9980] | Yes | ✅ Complete |
| **D2** | Single-Modality MLP | miRNA (383) | **0.9967 ± 0.0012** | [0.9952, 0.9982] | Yes | ✅ Complete |
| **D3** | Single-Modality MLP | CNV (3,105) | **0.8532 ± 0.0114** | [0.8391, 0.8674] | Yes | ✅ Complete |
| **D4** | Single-Modality MLP | Methy (3,139) | **0.9945 ± 0.0000** | [0.9945, 0.9945] | No (Deterministic) | ✅ Complete |
| **D5** | Early Fusion MLP | Concatenated (9,844) | **0.9961 ± 0.0015** | [0.9943, 0.9980] | Yes | ✅ Complete |
| **D6** | LightGBM (GBDT) | Concatenated (9,844) | **0.9973 ± 0.0000** | [0.9973, 0.9973] | No (Deterministic) | ✅ Complete |

*Baseline Scope Qualification:* Baselines D5 and D6 were evaluated strictly on complete 4-omics inputs (Condition C0); our model cannot be claimed to outperform them under missing modalities without further benchmarking with imputation. On complete inputs, LightGBM achieves the highest test Macro-F1 ($0.9973$).

### Stage E: Proposed Multimodal Cross-Attention Fusion Model

| Strategy | Training Description | Val Macro-F1 | Test Macro-F1 | 95% Confidence Interval | Status |
|:---:|:---|:---:|:---:|:---:|:---:|
| **S1** | Complete Modality Only ($p=0.0$) | 1.0000 ± 0.0000 | **0.9956 ± 0.0015** | [0.9937, 0.9975] | ✅ Complete |
| **S2** | Modality Dropout ($p=0.3$) | 1.0000 ± 0.0000 | **0.9950 ± 0.0012** | [0.9935, 0.9966] | ✅ Complete |

- All 10 model checkpoints (5 seeds $\times$ 2 strategies) successfully saved in `artifacts/models/`.

### Stage F: Missing-Modality Robustness Evaluation (15 Conditions C0–C14 across 5 Seeds)

| Condition | Missing Modality Description | S1 Mean ± Std | S2 Mean ± Std | Paired Mean Diff (Δ) | Paired Cohen's $d$ | Paired $t$ $p$-val | Wilcoxon $p$-val | 95% CI of Difference |
|:---:|:---|:---:|:---:|:---:|:---:|:---:|:---:|:---:|
| **C0** | Complete (reference) | 0.9956 ± 0.0015 | 0.9950 ± 0.0012 | -0.000552 | -0.2390 | 0.6213 | 1.0000 | [-0.0034, +0.0023] |
| **C1** | mRNA missing | 0.9939 ± 0.0012 | 0.9950 ± 0.0012 | +0.001107 | 0.4472 | 0.3739 | 1.0000 | [-0.0020, +0.0042] |
| **C2** | miRNA missing | 0.9945 ± 0.0000 | 0.9945 ± 0.0000 | +0.000000 | 0.0000 | 1.0000 | 1.0000 | [+0.0000, +0.0000] |
| **C3** | CNV missing | 0.9956 ± 0.0015 | 0.9967 ± 0.0012 | +0.001104 | 0.4472 | 0.3739 | 0.6250 | [-0.0020, +0.0042] |
| **C4** | Methy missing | 0.9956 ± 0.0015 | 0.9967 ± 0.0012 | +0.001104 | 0.4472 | 0.3739 | 0.6250 | [-0.0020, +0.0042] |
| **C5** | mRNA+miRNA missing | 0.9934 ± 0.0025 | 0.9938 ± 0.0015 | +0.000436 | 0.1357 | 0.7767 | 1.0000 | [-0.0036, +0.0044] |
| **C6** | mRNA+CNV missing | 0.9956 ± 0.0015 | 0.9956 ± 0.0015 | +0.000000 | 0.0000 | 1.0000 | 1.0000 | [-0.0034, +0.0034] |
| **C7** | mRNA+Methy missing | 0.9928 ± 0.0015 | 0.9939 ± 0.0030 | +0.001101 | 0.2641 | 0.5866 | 0.8750 | [-0.0041, +0.0063] |
| **C8** | miRNA+CNV missing | 0.9950 ± 0.0012 | 0.9950 ± 0.0012 | +0.000000 | 0.0000 | 1.0000 | 1.0000 | [-0.0024, +0.0024] |
| **C9** | miRNA+Methy missing | 0.9950 ± 0.0012 | 0.9950 ± 0.0012 | +0.000000 | 0.0000 | 1.0000 | 1.0000 | [-0.0024, +0.0024] |
| **C10** | CNV+Methy missing | 0.9973 ± 0.0000 | 0.9973 ± 0.0000 | +0.000000 | 0.0000 | 1.0000 | 1.0000 | [+0.0000, +0.0000] |
| **C11** | Only Methy present | 0.9923 ± 0.0050 | 0.9933 ± 0.0028 | +0.001001 | 0.1592 | 0.7399 | 1.0000 | [-0.0068, +0.0088] |
| **C12** | **Only CNV present** | **0.6561 ± 0.0892** | **0.7412 ± 0.0476** | **+0.085172** | **0.7425** | **0.1722** | **0.1875** | **[-0.0573, +0.2276]** |
| **C13** | Only miRNA present | 0.9915 ± 0.0034 | 0.9945 ± 0.0033 | +0.003006 | 0.6763 | 0.2050 | 0.1875 | [-0.0025, +0.0085] |
| **C14** | Only mRNA present | 0.9956 ± 0.0015 | 0.9973 ± 0.0000 | +0.001656 | 1.0954 | 0.0705 | 0.2500 | [-0.0002, +0.0035] |

**Scientific Interpretation for Condition C12:**
- S2 outperforms S1 on 4 out of 5 seeds ($+0.0045, +0.2717, +0.1120, -0.0112, +0.0489$).
- Paired mean difference is $+0.0852$ ($+8.52\%$) with paired Cohen's $d = 0.7425$.
- Because $N=5$ seeds ($df=4$), paired $t$-test yields $p=0.1722$ and Wilcoxon yields $p=0.1875$. This empirical gain is substantial but not statistically significant at $\alpha = 0.05$.
- Variance reflects **training initialization stochasticity**, not patient-population resample variance.

### Stage G: Explainability & Interpretability Scope
1. **Attention Routing (Descriptive):**
   - mRNA Attention: 34.0%
   - DNA Methylation Attention: 34.2%
   - miRNA Attention: 26.1%
   - CNV Attention: 5.7% (Autonomous downweighting of noisy structural signals; not causal proof).
2. **Computational Feature Attributions ($\text{Input} \times |\nabla_x|$):**
   - Literature concordance confirmed for *SFRP1* (BRCA), *ANO1* (HNSC), *PDGFRA* (LGG), and *DPP4* (THCA).
   - Qualified strictly as computational sensitivity interpretability, not causal biological proof or clinical biomarker validation.

### Stage H: Visualizations & Research Artifacts
- **Primary Presentation Package:** `reports/presentation_figures/` (Complete 24-artifact suite of 300 DPI figures, CSVs, manifest, and report).
  - **A1–A5:** Confusion matrices (raw & normalized), multiclass ROC (Macro AUC=0.9996), PR curves (Micro AP=0.9980), metrics tables, and checkpoint convergence analysis.
  - **B1–B5:** 15-condition performance (C12 +8.52% gain, p=0.1722 annotated), performance vs missing rate (0-75%), complete baseline comparison, single-modality confusion grid, and 4-panel ablation study.
  - **C1:** 2D t-SNE projections of R^128 fused metric space (C0 vs C12).
  - **D1–D4:** Model architecture, pipeline workflow, missingness handling mechanics, and dataset overview.
- **Legacy Artifacts:** `artifacts/figures/` (Figs 1–4).

### Stage I: Automated Test Suite
- Test Suite: `tests/test_pipeline.py`
- Execution Result: **8 passed in 9.98s** (100% green).
  1. `test_splits_no_leakage`: Passed (verified $\text{Train} \cap \text{Val} = \emptyset, \text{Train} \cap \text{Test} = \emptyset$).
  2. `test_processed_modality_shapes`: Passed (verified exact feature counts and zero NaNs).
  3. `test_model_forward_pass_and_attention`: Passed (verified shape and attention tensors).
  4. `test_missing_modality_handling`: Passed (verified forward pass under C12 masking).
  5. `test_metrics_computation`: Passed (verified Macro-F1, balanced accuracy, and confusion matrix).
  6. `test_masked_modality_numerical_invariance`: Passed (verified altering masked numerical values causes 0.0 change in evaluation logits).
  7. `test_all_15_evaluation_conditions_tensor_shapes_and_finite`: Passed (verified all 15 conditions output correct shapes and strictly finite values).
  8. `test_all_missing_numerical_safeguard`: Passed (verified all-missing mask outputs finite fallback prior without NaN).

### Stage J: Systematic Ablation Suite (A1–A4)
- Tokens: Learned default tokens reduce test variance by 35.2% under missing conditions.
- Dropout probability: $p=0.5$ elevates C12 to $0.7897 \pm 0.0107$ (+13.36% gain over S1).
- Latent dimension: $D=64$ to $128$ constrains manifold better than overparameterized $D=256$.
- Attention heads: $H=1$ collapses to $0.5907 \pm 0.1094$ on C12; $H=2$ and $H=4$ achieve $\sim 0.74$.

### Stage K: Statistical Hypothesis Testing & Confidence Intervals
- Machine-readable JSON: `artifacts/metrics/statistical_significance_tests.json`
- Tabular CSV: `reports/statistical_significance_report.csv`
- Markdown report: `reports/statistical_significance_report.md`
- Paired comparison implemented across all 15 conditions; baseline CIs computed strictly from actual per-seed runs without duplication.

### Stage L: Research Manuscript Draft
- Manuscript: `reports/research_paper_draft.md` (Working research manuscript draft, pre-peer-review).
